Evidence map›Paper›PMID 33458357›Full record

ArticlePhysics and imaging in radiation oncology2020

Imaging prior to radiotherapy impacts

Peter L Kench, Linda Rogers, Ana Esteves, Tina Gorjiara, Elizabeth Claridge Mackonis, Stephen Morrell, David R McKenzie, Natalka Suchowerska

Abstract read
In one paragraph

Article in Physics and imaging in radiation oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. [Advances in low-dose cone-beam computed tomography image reconstruction methods based on deep learning].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2025
    Review
  3. Article
  4. PCXMC cone beam computed tomography dosimetry investigations.Physical and engineering sciences in medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Peter L KenchDiscipline of Medical Imaging Science and Brain and Mind Centre, Faculty of Medicine and Health, University of Sydney, NSW 2006, Australia.
Linda RogersVectorLAB, Radiation Oncology, Chris O'Brien Lifehouse, Missenden Rd, Camperdown, Sydney, NSW 2050, Australia.
Ana EstevesDiscipline of Medical Imaging Science and Brain and Mind Centre, Faculty of Medicine and Health, University of Sydney, NSW 2006, Australia.
Tina GorjiaraVectorLAB, Radiation Oncology, Chris O'Brien Lifehouse, Missenden Rd, Camperdown, Sydney, NSW 2050, Australia.
Elizabeth Claridge MackonisVectorLAB, Radiation Oncology, Chris O'Brien Lifehouse, Missenden Rd, Camperdown, Sydney, NSW 2050, Australia.
Stephen MorrellUniversity of New South Wales, School of Public Health and Community Medicine, NSW 2052, Australia.
David R McKenzieVectorLAB, Radiation Oncology, Chris O'Brien Lifehouse, Missenden Rd, Camperdown, Sydney, NSW 2050, Australia.
Natalka SuchowerskaVectorLAB, Radiation Oncology, Chris O'Brien Lifehouse, Missenden Rd, Camperdown, Sydney, NSW 2050, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeCone Beam Computed Tomography (CBCT) is routinely used in radiotherapy to identify the position of the target volume. The aim of this study was to determine whether the CBCT dose, when followed by the treatment, influences the therapeutic outcomes as determined by in-vitro clonogenic cell survival in a radiobiological experiment. MATERIALS AND

methodsHuman cell lines, four cancer and one normal, were exposed to a 6 MV photon beam, produced by a linear accelerator. For half of each sample, a prior imaging dose was delivered using the on-board CBCT. A sample size of n = 103 was used to achieve statistical power.

resultsThe experimental group of cell lines exposed to CBCT imaging prior to treatment exhibited a reduction in mean cancer cell survival of ~17 times (p = 0.02) greater than predicted from the average dose response and equivalent to more than 5% of the therapeutic dose, compared to 11 times greater than predicted for normal cells (n.s.).

conclusionThe greater than predicted reduction in survival resulting from the additional CBCT dose is consistent with radiation-induced bystander effects.

Indexed as

CBCTClonogenic survivalImaging doseRadiation therapy

Identifiers

PMID33458357
PMCPMC7807556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.